[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SMT201700056B - Fosfaplatine e relativo utilizzo per il trattamento di cancro - Google Patents

Fosfaplatine e relativo utilizzo per il trattamento di cancro

Info

Publication number
SMT201700056B
SMT201700056B SM201700056T SM201700056T SMT201700056B SM T201700056 B SMT201700056 B SM T201700056B SM 201700056 T SM201700056 T SM 201700056T SM 201700056 T SM201700056 T SM 201700056T SM T201700056 B SMT201700056 B SM T201700056B
Authority
SM
San Marino
Prior art keywords
phosphaplatin
cancer treatment
related use
cancer
treatment
Prior art date
Application number
SM201700056T
Other languages
English (en)
Inventor
Rathindra N Bose
Original Assignee
Univ Ohio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44627266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201700056(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Ohio filed Critical Univ Ohio
Publication of SMT201700056B publication Critical patent/SMT201700056B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/245Bismuth; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086Platinum compounds
    • C07F15/0093Platinum compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SM201700056T 2010-06-04 2017-01-25 Fosfaplatine e relativo utilizzo per il trattamento di cancro SMT201700056B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35151410P 2010-06-04 2010-06-04
PCT/US2011/038948 WO2011153365A1 (en) 2010-06-04 2011-06-02 Phosphaplatins and their use for treatment of cancers

Publications (1)

Publication Number Publication Date
SMT201700056B true SMT201700056B (it) 2017-03-08

Family

ID=44627266

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201700056T SMT201700056B (it) 2010-06-04 2017-01-25 Fosfaplatine e relativo utilizzo per il trattamento di cancro

Country Status (30)

Country Link
US (4) US9688709B2 (it)
EP (1) EP2575802B1 (it)
JP (1) JP5860872B2 (it)
KR (1) KR101775410B1 (it)
CN (6) CN108392490A (it)
AP (1) AP3480A (it)
AU (1) AU2011261381B2 (it)
BR (1) BR112012030927B1 (it)
CA (1) CA2800898C (it)
CL (1) CL2012003416A1 (it)
CO (1) CO6640302A2 (it)
CY (1) CY1118466T1 (it)
DK (1) DK2575802T3 (it)
EA (1) EA021526B1 (it)
ES (1) ES2606855T3 (it)
HR (1) HRP20170225T1 (it)
HU (1) HUE030249T2 (it)
IL (1) IL223405B (it)
LT (1) LT2575802T (it)
MX (1) MX2012014174A (it)
MY (1) MY162902A (it)
NZ (1) NZ603952A (it)
PL (1) PL2575802T3 (it)
PT (1) PT2575802T (it)
RS (1) RS55714B1 (it)
SG (1) SG185722A1 (it)
SI (1) SI2575802T1 (it)
SM (1) SMT201700056B (it)
WO (1) WO2011153365A1 (it)
ZA (1) ZA201209007B (it)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2575802T3 (en) 2010-06-04 2017-01-09 Univ Ohio Phosphaplatiner and use thereof for the treatment of cancer
JP2014502634A (ja) * 2011-01-12 2014-02-03 オハイオ ユニバーシティー 抗血管新生、抗転移、及びアポトーシス促進の特性を有するホスファプラチン並びにそれらの使用
CA2851254A1 (en) * 2011-10-05 2013-04-11 Shadi MOGHADDAS Efficient processes for large scale preparation of phophaplatins antitumor agents
EP2763537B1 (en) * 2011-10-05 2018-01-10 Rathindra N. Bose Efficient processes for large scale preparation of phosphaplatins antitumor agents
HUE032197T2 (en) 2012-05-24 2017-09-28 Phosplatin Therapeutics Llc Methods of synthesis and purification for the preparation of phosphaplatin compounds and their applications
WO2014130776A1 (en) 2013-02-22 2014-08-28 University Of Houston Phosphaplatins as neuroprotective agents
US20150231151A1 (en) * 2014-02-19 2015-08-20 University Of Houston System Compositions and methods for the treatment of neurodegenerative diseases
US11154529B2 (en) * 2016-04-06 2021-10-26 Phosplatin Therapeutics Inc. Phosphaplatin liquid formulations
JP7023968B2 (ja) * 2017-01-06 2022-02-22 フォスプラティン・セラピューティクス・インコーポレーテッド 骨がんまたは血液がんの治療のための治療薬としてのホスファプラチン化合物
AU2018327339B2 (en) * 2017-09-08 2023-10-12 Promontory Therapeutics Inc. Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof
US20240009212A1 (en) * 2020-10-20 2024-01-11 Promontory Therapeutics Inc. Phosphaplatin compounds as therapeutic agents selectively targeting highly glycolytic tumor cells and methods thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234500A (en) 1979-03-07 1980-11-18 Engelhard Minerals & Chemicals Corporation Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes
US4291027A (en) 1979-03-07 1981-09-22 Engelhard Minerals & Chemicals Corp. Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes
CA2017739A1 (en) 1989-07-18 1991-01-18 Leslie S. Hollis Cis-diamineplatinum complexes with methanediphosphonate and substituted methanediphosphonate ligands as antitumor agents
AUPR330201A0 (en) 2001-02-23 2001-03-22 University Of Sydney, The Metal complexes and therapeutic uses thereof
DE10314780A1 (de) 2003-03-19 2004-09-30 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Derivate von Platinkomplexen mit Cyclobutan-1,1-dicarboxylatliganden
AU2004235781A1 (en) 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
EP1644388A2 (en) 2003-06-27 2006-04-12 ODANI, Akira Bisphosphonate complexes
EP2177525A1 (en) 2007-07-06 2010-04-21 TMRC Co., Ltd. Metal complex compound, cancer therapeutic composition comprising the metal complex compound as active ingredient, and intermediate for production of the metal complex compound
WO2009021082A2 (en) * 2007-08-06 2009-02-12 Ohio University Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin
JP5553275B2 (ja) 2010-03-31 2014-07-16 国立大学法人金沢大学 金属錯体およびこれを有効成分として含有する抗がん剤
DK2575802T3 (en) 2010-06-04 2017-01-09 Univ Ohio Phosphaplatiner and use thereof for the treatment of cancer
JP2014502634A (ja) 2011-01-12 2014-02-03 オハイオ ユニバーシティー 抗血管新生、抗転移、及びアポトーシス促進の特性を有するホスファプラチン並びにそれらの使用
EP2763537B1 (en) * 2011-10-05 2018-01-10 Rathindra N. Bose Efficient processes for large scale preparation of phosphaplatins antitumor agents

Also Published As

Publication number Publication date
MY162902A (en) 2017-07-31
US20130064902A1 (en) 2013-03-14
WO2011153365A1 (en) 2011-12-08
NZ603952A (en) 2014-07-25
DK2575802T3 (en) 2017-01-09
PL2575802T3 (pl) 2017-04-28
AP2012006594A0 (en) 2012-12-31
CN108392490A (zh) 2018-08-14
KR101775410B1 (ko) 2017-09-06
AP3480A (en) 2015-12-31
JP2013529219A (ja) 2013-07-18
LT2575802T (lt) 2016-12-27
ZA201209007B (en) 2013-08-28
ES2606855T3 (es) 2017-03-28
US10759820B2 (en) 2020-09-01
EA021526B1 (ru) 2015-07-30
AU2011261381B2 (en) 2015-04-02
KR20130095244A (ko) 2013-08-27
US10385083B2 (en) 2019-08-20
CN108186651A (zh) 2018-06-22
HRP20170225T1 (hr) 2017-04-07
EP2575802B1 (en) 2016-11-16
BR112012030927B1 (pt) 2021-09-21
SG185722A1 (en) 2013-01-30
CN108210516A (zh) 2018-06-29
RS55714B1 (sr) 2017-07-31
EA201270812A1 (ru) 2013-05-30
CN108409795B (zh) 2024-09-27
CO6640302A2 (es) 2013-03-22
SI2575802T1 (sl) 2017-03-31
US20170327521A1 (en) 2017-11-16
CN108409795A (zh) 2018-08-17
CY1118466T1 (el) 2017-07-12
EP2575802A1 (en) 2013-04-10
CN108299508A (zh) 2018-07-20
AU2011261381A1 (en) 2013-01-10
CA2800898C (en) 2018-12-04
CN103037859A (zh) 2013-04-10
MX2012014174A (es) 2013-07-03
PT2575802T (pt) 2016-12-27
US9688709B2 (en) 2017-06-27
BR112012030927A2 (pt) 2017-12-05
JP5860872B2 (ja) 2016-02-16
US20190315789A1 (en) 2019-10-17
US20170327522A1 (en) 2017-11-16
HUE030249T2 (en) 2017-04-28
US10364264B2 (en) 2019-07-30
CL2012003416A1 (es) 2013-09-06
CA2800898A1 (en) 2011-12-08
IL223405B (en) 2018-11-29

Similar Documents

Publication Publication Date Title
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
SMT201600430B (it) Inibitori di chinasi e loro uso nel trattamento del cancro
SMT201600370B (it) Complessi chelati di oligonucleotidi
BR112012005594A2 (pt) tratamento de câncer
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
BR112014009755A2 (pt) tratamento de câncer com inibidores de quinase tor
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
IT1400425B1 (it) Modified snrnas for use in therapy.
BR112014007603A2 (pt) métodos de tratamento do câncer
DE112011100715T8 (de) Hardware-hilfs-thread
ES2638522T8 (es) Procedimientos para detectar cáncer
BRPI1008566A8 (pt) métodos e composições para o diagnóstico e tratamento de câncer
SG10201508495VA (en) Combination treatment of cancer
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BR112014012880A2 (pt) tratamento imunogênico do câncer
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
BR112013011659A2 (pt) métodos de tratamento do câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
EP2603222A4 (en) COMBINATIVE CANCER TREATMENT
IL222958A0 (en) Cancer treatment
DK2642992T3 (da) Forbindelser og anvendelse deraf
EP2773340A4 (en) USE OF SIALIDASE INHIBITORS (NEU1) IN THE TREATMENT OF CANCER
BR112013023452A2 (pt) combinação de oligonucleotídeo anti-clusterina com inibidor de hsp90 para o tratamento de câncer de próstata
IT1398438B1 (it) Dispositivo di premacinazione e relativo procedimento